NeurogesX Sets IPO Terms

NeurogesX Inc., a San Carlos, Calif.-based drug company focused on pain management therapies, has set its proposed IPO terms to 4 million common shares being offered at between $13 and $15 per share. It plans to trade on the Nasdaq under ticker symbol NGSX, with Morgan Stanley serving as lead underwriter. The company has raised around $90 million in VC funding since 2000, from firms like ARCH Venture Partners (24.7% pre-IPO stake), Alta Partners (18.6%), Walden International (14.3%) Montreaux Equity Partners (10.2%) and Global Life Sciences Ventures (4.4%).